Janux Therapeutics Q1 2024: Cash $651.8M; net loss $14.8M; trials ongoing

Janux Therapeutics, Inc.

2024-Q1 EPS reported -$0.30 revenue$1,252,000

Cash and short-term investments $651.8M as of March 31, 2024, up from $344.0M at Dec 31, 2023.
Net loss $14.8M for Q1 2024, improved from $17.5M in Q1 2023; R&D expenses $14.1M vs $15.9M.
Enrollment ongoing in Phase 1 trials for JANX007 (PSMA-TRACTr in mCRPC) and JANX008 (EGFR-TRACTr in solid tumors).
JANX007 data update and expansion cohort doses anticipated in 2H 2024; JANX008 data expected in 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Janux Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income Net loss of $14.8 million.

Period: first quarter ended March 31, 2024
Net income: Net loss of $14.8 million
Result: reported results

Exact text from the filing

Janux Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2024.

View on SEC.gov

1050 earnings releases filed in the last 30 days. Browse all earnings releases →

Janux Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-054950

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.